AFMD

Affimed N.V. [AFMD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AFMD Stock Summary

AFMD has more than 11 years of cash runway (134 months)

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 25.54%

Earnings are expected to fall -100% next year

Profit margins (-2.63%) are lower than the previous year (-2.08%)

Top 10 Correlated Stocks

AFMD

In the News

06:30 10 Jun 2023 AFMD

Affimed to Present at the 2023 Jefferies Healthcare Conference

HEIDELBERG, Germany, May 30, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

12:36 10 Jun 2023 AFMD

Affimed N.V. (AFMD) Q1 2023 Earnings Call Transcript

Affimed N.V. (NASDAQ:AFMD ) Q1 2023 Earnings Conference Call May 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Arndt Schottelius - Chief Scientific Officer Conference Call Participants Maurice Raycroft - Jefferies Li Watsek - Cantor Fitzgerald Srikripa Devarakonda - Truist Securities Bradley Canino - Stifel Yale Jen - Laidlaw Yanan Zhu - Wells Fargo Securities Operator Good day, everyone and welcome to Affimed's First Quarter 2023 Earnings and Corporate Update Call.

08:53 10 Jun 2023 AFMD

Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates

Affimed N.V. (AFMD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22.

06:30 10 Jun 2023 AFMD

Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.

09:08 10 Jun 2023 AFMD

Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022.

06:30 10 Jun 2023 AFMD

Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.

06:30 10 Jun 2023 AFMD

Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference

HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.

06:30 10 Jun 2023 AFMD

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities 2023 Global Biopharma Conference on Tuesday, February 14, 2023 at 2:20 p.m. EST / 20:20 CET.

01:58 10 Jun 2023 AFMD

7 Cheap But Risky Biotech Stocks

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

11:18 10 Jun 2023 AFMD

Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

AFMD Financial details

Company Rating

Buy

Market Cap

131.07M

Income

-99.64M

Revenue

37.86M

Book val./share

0.84

Cash/share

1.04

Dividend

Dividend %

Employees

219

Optionable

Shortable

Yes

Earnings

09 Aug 2023

P/E

-0.97

Forward P/E

PEG

-0.23

P/S

2.55

P/B

0.77

P/C

0.69

P/FCF

-0.87

Quick Ratio

5.08

Current Ratio

5.21

Debt / Equity

0.34

LT Debt / Equity

0.08

EPS (TTM)

-0.68

EPS next Y

EPS next Q

EPS this Y

25%

EPS next Y

EPS next 5Y

EPS last 5Y

13.4%

Revenue last 5Y

11.74%

Revenue Q/Q

-59.58%

EPS Q/Q

-19.23%

SMA20

SMA50

SMA100

Inst Own

39.64%

Inst Trans

-15.22%

ROA

-59%

ROE

-61%

ROC

-0.75%

Gross Margin

100%

Oper. Margin

-271%

Profit Margin

-263%

Payout

Shs Outstand

149.34M

Shs Float

125.56M

Target Price

52W Range

0.55-3.4

52W High

52W Low

RSI

Rel Volume

1.58

Avg Volume

750.01K

Volume

1.18M

Perf Week

-15.75%

Perf Month

-20.09%

Perf Quarter

-35.79%

Perf Half Y

-63.86%

Beta

2.51795

Volatility

0.06%, 0.09%

Prev Close

3.39%

Price

0.7192

Change

-6.35%

AFMD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0.39	0.33	0.34	0.34	0.29
Net income per share	-0.32	-0.5	-0.5	-0.48	-0.6
Operating cash flow per share	0.82	-0.45	-0.23	-0.72	-0.74
Free cash flow per share	0.81	-0.48	-0.24	-0.76	-0.74
Cash per share	1.8	1.62	1.76	1.65	1.34
Book value per share	0.66	0.6	0.86	1.14	1.07
Tangible book value per share	0.66	0.6	0.84	1.12	1.07
Share holders equity per share	0.66	0.6	0.86	1.14	1.07
Interest debt per share	0.09	0.06	0.02	0.16	0.14
Market cap	164.4M	157.14M	399.19M	582.47M	165.33M
Enterprise value	74.34M	65.09M	253.63M	403.53M	-6.76M
P/E ratio	-8.44	-4.86	-9.65	-10.13	-1.92
Price to sales ratio	6.93	7.35	14.08	14.43	4
POCF ratio	3.33	-5.41	-20.58	-6.73	-1.58
PFCF ratio	3.37	-5.15	-20.12	-6.44	-1.57
P/B Ratio	4.1	4.06	5.54	4.28	1.08
PTB ratio	4.1	4.06	5.54	4.28	1.08
EV to sales	3.13	3.04	8.94	10	-0.16
Enterprise value over EBITDA	-4.08	-2.1	-7.41	-6.3	0.08
EV to operating cash flow	1.5	-2.24	-13.07	-4.66	0.06
EV to free cash flow	1.53	-2.13	-12.78	-4.46	0.06
Earnings yield	-0.12	-0.21	-0.1	-0.1	-0.52
Free cash flow yield	0.3	-0.19	-0.05	-0.16	-0.64
Debt to equity	1.9	1.91	1.44	0.66	0.31
Debt to assets	0.65	0.66	0.59	0.4	0.24
Net debt to EBITDA	4.94	2.96	4.25	2.8	1.99
Current ratio	3.01	3.01	2.25	3.2	5.66
Interest coverage	-23.06	-67.03	-365.45	-89.93	-54.06
Income quality	-2.54	0.9	0.47	1.51	1.22
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.41	0.48	0.48	0.6	0.78
Research and developement to revenue	1.48	2.05	1.76	2.02	2.39
Intangibles to total assets	0	0	0.01	0.01	0
Capex to operating cash flow	-0.01	0.05	0.02	0.04	0.01
Capex to revenue	-0.03	-0.07	-0.02	-0.1	-0.02
Capex to depreciation	-1.79	-1.63	-0.39	-2.89	-0.24
Stock based compensation to revenue	0.09	0.12	0.12	0.29	0.46
Graham number	2.19	2.61	3.1	3.51	3.82
ROIC	0.24	0.36	0.27	0.34	0.44
Return on tangible assets	-0.17	-0.29	-0.24	-0.26	-0.43
Graham Net	0.56	0.49	0.54	0.94	1.02
Working capital	74.04M	70.73M	83.77M	141.85M	161.42M
Tangible asset value	40.07M	38.53M	70.28M	134.34M	152.86M
Net current asset value	34.83M	32.22M	47.07M	117.21M	148.47M
Invested capital	0.12	0.08	0.02	0.14	0.12
Average receivables	1.27M	1.46M	1.96M	3.62M	3.75M
Average payables	6.8M	10.05M	11.03M	15.13M	18.97M
Average inventory	250.5K	278K	271K	333.5K	524.5K
Days sales outstanding	21.98	25.29	31.39	43.48	23.8
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	16.61	14.43	11.63	8.39	15.33
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.49	-0.84	-0.57	-0.42	-0.56
Capex per share	-0.01	-0.02	-0.01	-0.03	0

Quarterly Fundamentals Overview

Last date of statement is 2023-03-31 for Q1

Metric	2022-03-31	2022-06-30	2022-09-30	2022-12-31	2023-03-31
Revenue per share	0.06	0.05	0.1	0.08	0.03
Net income per share	-0.14	-0.12	-0.09	-0.26	-0.21
Operating cash flow per share	-0.23	-0.18	-0.13	-0.22	-0.22
Free cash flow per share	-0.23	-0.18	-0.13	-0.22	-0.22
Cash per share	1.38	1.61	1.49	1.34	1.04
Book value per share	0.95	1.31	1.21	1.07	0.84
Tangible book value per share	0.95	1.31	1.21	1.07	0.84
Share holders equity per share	0.95	1.31	1.21	1.07	0.84
Interest debt per share	0.15	0.13	0.13	0.13	0.12
Market cap	488.2M	391.28M	312.97M	165.33M	102.11M
Enterprise value	336.99M	172.84M	108.81M	-6.76M	-37.02M
P/E ratio	-7.32	-5.7	-5.68	-1.13	-0.8
Price to sales ratio	60.98	53.59	21.02	14.82	22.64
POCF ratio	-17.18	-14.77	-16.45	-5.34	-3.07
PFCF ratio	-17.11	-14.73	-16.36	-5.27	-3.07
P/B Ratio	4.16	2.03	1.73	1.08	0.82
PTB ratio	4.16	2.03	1.73	1.08	0.82
EV to sales	42.09	23.67	7.31	-0.61	-8.21
Enterprise value over EBITDA	-20	-8.1	-5.81	0.24	1.21
EV to operating cash flow	-11.86	-6.53	-5.72	0.22	1.11
EV to free cash flow	-11.81	-6.5	-5.69	0.22	1.11
Earnings yield	-0.03	-0.04	-0.04	-0.22	-0.31
Free cash flow yield	-0.06	-0.07	-0.06	-0.19	-0.33
Debt to equity	0.65	0.35	0.31	0.31	0.34
Debt to assets	0.39	0.26	0.23	0.24	0.26
Net debt to EBITDA	8.98	10.24	10.9	6.18	4.54
Current ratio	3.13	4.9	5.65	5.66	5.21
Interest coverage	-45.33	-56.86	-47.08	-65.04	-65.96
Income quality	1.71	1.36	1.15	0.93	1.04
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.88	1.15	0.54	0.77	1.52
Research and developement to revenue	2.3	2.85	1.75	3	6.55
Intangibles to total assets	0.01	0.01	0.01	0	0
Capex to operating cash flow	0	0	0.01	0.01	0
Capex to revenue	-0.01	-0.01	-0.01	-0.04	0
Capex to depreciation	-0.3	-0.25	-0.27	-0.22	-0.03
Stock based compensation to revenue	0.53	0.77	0.33	0.39	0.92
Graham number	1.7	1.85	1.59	2.5	2.01
ROIC	0.11	0.08	0.07	0.17	0.19
Return on tangible assets	-0.09	-0.07	-0.06	-0.18	-0.19
Graham Net	0.79	1.18	1.13	1.02	0.78
Working capital	123.14M	202.78M	189.72M	161.42M	132.36M
Tangible asset value	115.84M	191.27M	179.55M	152.86M	125.04M
Net current asset value	105.1M	186.71M	175.25M	148.47M	120.93M
Invested capital	0.16	0.1	0.1	0.12	0.13
Average receivables	4.68M	5.04M	3.61M	2.19M	3.22M
Average payables	16.2M	13.15M	13.92M	17.08M	19.61M
Average inventory	453K	528K	622K	650.5K	647.5K
Days sales outstanding	51.12	68.09	10.22	21.75	74.67
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	1.76	1.32	8.8	4.14	1.21
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.14	-0.09	-0.08	-0.24	-0.26
Capex per share	0	0	0	0	0

AFMD Frequently Asked Questions

What is Affimed N.V. stock symbol ?

Affimed N.V. is a DE stock and trading under the symbol AFMD

What is Affimed N.V. stock quote today ?

Affimed N.V. stock price is $0.7192 today.

Is Affimed N.V. stock public?

Yes, Affimed N.V. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 750.01K
Market Capitalization 131.07M
Employee 219
CEO Dr. Adi Hoess M.D., Ph.D.
Headquarters Heidelberg,DE
IPO Date 2014-09-12
Website https://www.affimed.com

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.